Evidence map›Paper›PMID 37431963›Full record

ArticleThe EMBO journal2023

Loss of TDP-43 oligomerization or RNA binding elicits distinct aggregation patterns.

Manuela Pérez-Berlanga, Vera I Wiersma, Aurélie Zbinden, Laura De Vos, Ulrich Wagner, Chiara Foglieni, Izaskun Mallona, Katharina M Betz, Antoine Cléry, Julien Weber and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in The EMBO journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
17.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. TDP-43: [GU]-ardian of the transcriptome.Molecular neurodegeneration · 2026
    Review
  7. [Mechanisms of RNA-binding protein phase separation in steroid-associated necrosis of the femoral head].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Regulation of RNA-binding proteins by small biomolecules.Nature reviews. Molecular cell biology · 2026
    Review
  14. Article
  15. Review
  16. Ubiquitin Proteasome System Components, RAD23A and USP13, Modulate TDP-43 Solubility and Neuronal Toxicity.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  17. Review
  18. Article
  19. Article
  20. Neurodegenerative spliceosomopathies.Frontiers in cell and developmental biology · 2026
    Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Manuela Pérez-BerlangaDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-9064-9724
Vera I Wiersma *Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-8223-4588
Aurélie Zbinden *Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-7785-2741
Laura De VosDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-6675-6968
Ulrich WagnerDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Chiara FoglieniNeurodegeneration Research Group, Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Izaskun MallonaDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-2853-7526
Katharina M BetzDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-5041-6205
Antoine CléryDepartment of Biology, Institute of Biochemistry, ETH Zurich, Zurich, Switzerland.ORCID 0000-0002-4550-6908
Julien WeberDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Zhongning GuoDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Ruben RigortDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-1686-3260
Pierre de RossiDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-2356-4269
Ruchi MangluniaDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Elena TantardiniDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Sonu SahadevanDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Oliver StachDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.
Marian Hruska-PlochanDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-9253-4362
Frederic H-T AllainDepartment of Biology, Institute of Biochemistry, ETH Zurich, Zurich, Switzerland.
Paolo PaganettiNeurodegeneration Research Group, Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.ORCID 0000-0003-1896-6324
Magdalini PolymenidouDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-1271-9445
University of Zurich · CHETH Zurich · CHLaboratory for Biomedical Neurosciences · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aggregation of the RNA-binding protein TAR DNA-binding protein 43 (TDP-43) is the key neuropathological feature of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). In physiological conditions, TDP-43 is predominantly nuclear, forms oligomers, and is contained in biomolecular condensates assembled by liquid-liquid phase separation (LLPS). In disease, TDP-43 forms cytoplasmic or intranuclear inclusions. How TDP-43 transitions from physiological to pathological states remains poorly understood. Using a variety of cellular systems to express structure-based TDP-43 variants, including human neurons and cell lines with near-physiological expression levels, we show that oligomerization and RNA binding govern TDP-43 stability, splicing functionality, LLPS, and subcellular localization. Importantly, our data reveal that TDP-43 oligomerization is modulated by RNA binding. By mimicking the impaired proteasomal activity observed in ALS/FTLD patients, we found that monomeric TDP-43 forms inclusions in the cytoplasm, whereas its RNA binding-deficient counterpart aggregated in the nucleus. These differentially localized aggregates emerged via distinct pathways: LLPS-driven aggregation in the nucleus and aggresome-dependent inclusion formation in the cytoplasm. Therefore, our work unravels the origins of heterogeneous pathological species reminiscent of those occurring in TDP-43 proteinopathy patients.

Indexed as

Amyotrophic Lateral SclerosisFrontotemporal Lobar DegenerationDNA-Binding ProteinsHumansNeuronsRNADNA-Binding ProteinsRNAaggregationLLPSoligomerizationRNATDP-43

Identifiers

PMID37431963
PMCPMC10476175
OpenAlexW4383872054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.